Re-Named Programs. If any program licensed under this ordering document (“Original Program”) is re-named or divided into two or more separate programs (“Re-Named Program”) and the functionality of the Re-Named Program is and remains the same as the functionality of the Original Program, and Oracle makes such Re-Named Program generally available at no additional license fees to all of its customers who have maintained technical support for the Original Program, then Oracle shall provide the Re-Named Program to you for no additional license fees, provided that the Re-Named Program is available in production release and that you have continuously maintained technical support for the Original Program pursuant to Oracle’s Technical Support Policies (or reinstated technical support for such program pursuant to Oracle’s then current Technical Support Policies). Technical Contact Xxxxx Xxxxxx Contract Administrator Xxxx Xxxxxx / Legal Location 0000 Xxxxxx Xxxx. Location 0000 Xxxxxx Xxxx. Xxxxxx, XX 00000 Xxxxxx, XX 00000 Contact Contact Phone 0000 000-0000 Phone 000-000-0000 Fax Fax Email Address dbrochu@taleo .com Email Address xxxxxxx@xxxxx.xxx This quote is valid through May 30, 2007 and shall become binding upon execution by you and acceptance by Oracle. TALEO CORPORATION ORACLE USA, INC. Signature /s/ Xxxx Xxxxxx Signature /s/ Xxxxxxxx X. Xxxxx Name Xxxx Xxxxxx Name Xxxxxxxx X. Xxxxx Title VP & Corp Counsel Title Director, License Contract Services Signature Date 5-30-07 Signature Date 5-30-07 8:41 pm PST Effective Date 5-30-07 (to be completed by Oracle) [*******] Confidential treatment requested. Exhibit A Terminated Licenses Exhibit Program License Type Quantity CSI Number Oracle Database Enterprise Edition Processor [*******] [*******] Oracle Database Enterprise Edition Processor [*******] [*******] Oracle Database Enterprise Edition Processor [*******] [*******] Oracle Database Enterprise Edition Processor [*******] [*******] Oracle Database Enterprise Edition Processor [*******] [*******] Oracle Database Enterprise Edition Processor [*******] [*******] Tuning Pack Processor [*******] [*******] Tuning Pack Processor [*******] [*******] Tuning Pack Processor [*******] [*******] Tuning Pack Processor [*******] [*******] Tuning Pack Processor [*******] [*******] Diagnostics Pack Processor [*******] [*******] Diagnostics Pack Processor [*******] [*******] Diagnostics Pack Processor [*******] [*******] Diagnostics Pack Processor [*******] [*******] Diagnostics Pack Processor [*...

Re-Named Programs. If any Program licensed under this Ordering Document (“Original Program”) is re-named or divided into two or more separate Programs (“Re-Named Program”) and the functionality of the Re-Named Program is and remains the same as the functionality of the Original Program, and the Contractor makes such Re-Named Program generally available at no additional license fees to all of its customers who have maintained Technical Support for the Original Program, then the Contractor shall provide the Re- Named Program to the State for no additional license fees, provided that the Re-Named Program is available in production release and that the State is current on Technical Support for the Original Program pursuant to the Contractor's Technical Support Policies (or reinstated Technical Support for such Program pursuant to the Contractor's then current Technical Support Policies).

Related to Re-Named Programs

Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:
Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.
Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.
Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).
Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.
Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.
Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.
Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.
Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.
Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

Re-Named Programs Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Sub-Clauses

Related to Re-Named Programs